Juvisé acquired the rights to Ponvory from Actelion Pharmaceutical (Johnson & Johnson) for its global commercialization, excluding the US & Canada , for the 1L treatment of adults with active forms of relapsing multiple sclerosis (RMS)
While the financial details remain undisclosed, the acquisition was funded by a series of capital increases, additional debt, shareholder loans & the acquisition of minority stakes in Juvisé by Bpifrance & Pemberton
Ponvory has shown superior efficacy results vs teriflunomide under P-III (OPTIMUM) clinical evaluation of adult patients with active RMS & has also shown a 30.5% reduction in Annualized Relapse Rate (1EP) & a significant reduction in MRI activity & fatigue (2EPs)
Ref: Businesswire | Image: Actelion
Related News:- Vanda Pharmaceuticals to Acquire the US and Canadian Rights for Ponvory from Actelion to Treat Relapsing Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
